Skip to content
Menu

Sonic Incytes Medical Announces Multi-Year Partnership With Madrigal Pharma To Advance Assessment And Risk Stratification Of Patients With Or At Risk For MASH

Benzinga Newsdesk 4 hours ago

News

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Partnership aims to help more clinicians assess and risk-stratify patients with or at risk for metabolic dysfunction-associated steatohepatitis (MASH), using point-of-care liver assessment.Sonic Incytes Medical Corp.,

Partnership aims to help more clinicians assess and risk-stratify patients with or at risk for metabolic dysfunction-associated steatohepatitis (MASH), using point-of-care liver assessment.

Sonic Incytes Medical Corp., developer of the Velacur™ point-of-care liver assessment platform, today announced a multi-year partnership with Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for MASH, to advance the assessment and risk stratification of patients with or at risk for MASH.

Read at benzinga.com